Natalie Dewberry-Moore, MS

Ms. Dewberry-Moore is a Patient Recruitment Specialist in Clinical Operations (CROps) at Merck & Co. She is responsible for developing and implementing strategic and tactical patient recruitment plans for several therapeutic areas in Phase IIA-IV Clinical Trials. Prior to working in CROps, Ms. Dewberry-Moore was a Clinical Research Associate in Diabetes. She also possesses a BS in Chemistry from Coppin State College and a MS in Community Health from Towson University, and she is a graduate of the UMDNJ Certificate in Recruitment Sciences. Her special interest area includes minority subject recruitment for clinical trials and the development of women and minority principal investigators.

Madeline Ducate, MS, MPH, MA, CCRA

Ms. Ducate is currently the Vice President of Global Operations for Pharm-Olam International with responsibilities in over 25 countries. She began her CRO career after spending 13 years in clinical laboratory sciences as a certified Specialist in Clinical and as a faculty member at UMDNJ. For the past 20+ years, Ms. Ducate has been leading efforts in global and multinational drug development, with first-hand experience in all aspects of clinical trial planning, implementation and monitoring throughout the world.

Lars-Olof Eriksson, MsSc, PhD

Dr. Eriksson is the Vice President of the “Start-up and Accelerated Recruitment Team” (START) at PAREXEL International, a global Clinical Research Organization (CRO) serving the pharmaceutical, biotechnology and medical device industry. Trained as a clinical pharmacologist he spent almost 30-years with Merck & Co., Inc. where he held various positions within Merck Research Laboratories (MRL), including clinical pharmacology, clinical research development and clinical research operations. He has worked across therapeutic areas, development phases and held various senior positions and responsibilities in Scandinavia, Europe, and Latin America. He was instrumental in incorporating the Eastern European countries into Merck clinical development programs and has extensive clinical research operation experience from the Asian region. During the last 10-15 years he has focused on research methodology and business development in clinical research with particular focus on site related activities. His main areas of focus are around interdependencies between medical informatics, procedures & infrastructure at a clinical research unit and cost-effective recruitment strategies. Dr. Eriksson is a frequent speaker at industry conferences and has authored several publications on the topics of patient recruitment, site management & performance, and drug development.

Robin Eubanks, PhD

Dr. Robin Eubanks is an Associate Professor at the University of Medicine and Dentistry of New Jersey – School of Health Related Professions in the Department of Interdisciplinary Studies. Dr. Eubanks has a Bachelor’s degree from Dickinson College, a Master’s degree from Adelphi University, and a Ph.D. in Counseling Psychology at Seton Hall University. She was privileged to receive a Student Research Recognition Award, African American Achievement Award, Excellence in Teaching Award and the University of Excellence Award, service to external community education. Dr. Eubanks teaches a variety of courses such as Cultural Issues in Health Care, Transcultural Health Care, Educational Methodology, Human Resources Management in Health Care, and Social & Cultural Diversity Issues in Psychiatric Rehabilitation. In addition she has presented workshops on a variety of topics such as: cultural perspectives in health care, resilience, motivation, and stress management. Dr. Eubanks is very active in her community. She was a Fellow in the Leadership Newark Organization, she has assisted with the design of a training curriculum for Community Health Workers in the Camden area, and she is a mentor for the NAACP ACTSO program for high school students in the Essex county area.

Deborah Flint, MS, MBA

Currently, an Associate Director, CMC Regulatory Affairs at Bayer Healthcare Pharmaceuticals, Ms. Flint has over 18 years of varied experience within the pharmaceutical and biotech industries. Previously, she has worked at Sanofi-Aventis, Genta, Pfizer and SmithKline Beecham Consumer Healthcare as well as an independent consultant. In addition to Regulatory Affairs, she has extensive experience in clinical and CMC Quality Assurance, and in formulations and manufacturing. An active member of the RAPS NY/NJ Chapter, Ms. Flint has held office three times, once as program chair and twice on the membership committee.

Laurence Flint, MD, MS, MBA, RAC, FAAP

Dr. Flint is a board-certified pediatrician with over 18 years in the pharmaceutical and biotech industry. He has experience in all phases of drug development from drug discovery through post approval clinical studies, specifically in the areas regulatory strategy and global clinical research. Previously employed at Johnson & Johnson and as an independent consultant, he is currently Associate Director, Clinical Research at the Schering-Plough Research Institute in Kenilworth, NJ. In addition to his clinical research work, Dr. Flint is also a practicing pediatric hospitalist.

David M. Gibson, Ed.D., FASAHP

Dr. Gibson is Professor Emeritus in the School of Health Related Professions.  Although recently retired as Dean, he continues to provide teaching expertise particularly in online education.  His research interests are focused on higher education issues including cultural issues in higher education, international education, and the humanities in health professions education.  He also has taught sessions on ethics and scientific misconduct in research.  In addition to his long tenure at UMDNJ, Dr. Gibson has been active with the Association of Schools of Allied Health Professions having served as both President of the Association, and Chair of the Association’s External and Government Relations Committee.  He also has had adjunct professor appointments at MISR University of Science and Technology, 6th October City, Egypt and Seton Hall University, South Orange.  Dr. Gibson played an instrumental role in the development of the Biopharma Educational Initiative as the Chief Academic Officer.

Barbara Gladson, MS, PhD

Dr. Gladson is the Director of the UMDNJ BioPharma Educational Initiative. She is a Professor with appointments in both the School of Health Related Professions and the Graduate School of Biomedical Sciences at the University of Medicine and Dentistry of New Jersey. Dr. Gladson's areas of teaching include Medical Pathophysiology, Pharmacokinetics, Cultural Diversity in Clinical Trials and Pharmacology. She has developed several web-based courses and has recently completed a textbook in pharmacology. Dr. Gladson is intricately involved in the University’s efforts to improve subject recruitment in clinical trials as well as in educating the public on the value of participating in a clinical trial.

Judy Harrison, MD

Dr. Harrison is an independent consultant to the MedDRA Maintenance and Support Services Organization (MSSO) and her responsibilities as a Medical Officer include terminology development, training, and providing general medical support. She has 20 years’ experience in clinical research and pharmacovigilance in the pharmaceutical industry including positions at Bayer in the U.K. and Schering-Plough in the U.S. She is currently an independent contractor and her company, Harrison Clinical Consulting, LLC, provides consulting services to pharmaceutical companies in addition to the MSSO. In addition, she is the chair of a Data Safety Monitoring Board for the National Institute on Deafness and Other Communication Disorders at the National Institutes of Health. Dr. Harrison received her undergraduate degree from the University of Cambridge and her medical degree from the University of Oxford.

Syed S. Haque, PhD

Syed Haque is Professor and Chair of the Department of Health Informatics at UMDNJ. His interest areas include health care outcomes measurement and research and health care data mining. He has published extensively in journals and in several conferences, and has also served as Chair in several international conferences. He has been Recognized/Certified as Internationally Registered Technology Specialist (IR7), by the Secretariat to the IRTS Council, International Technology Institute, San Diego, CA. He is also on the Editorial Board of The Journal on Information Technology in Healthcare.

David L. Hom, MS

Mr. Hom is an Assistant Professor in the Department of Primary Care and the External Grant Advisor in the School of Health Related. He has over 20 years experience in the development, conduct and management of IND phase I-III clinical trials. His initial work including working onsite in Uganda, in the early 1990’s as part of a research team established by Case Western Reserve University and Makerere University conducting early research into HIV/AIDS pathogenesis and associated opportunistic infections. Later trials included a large phase III trial of preventive therapy for TB in high-risk PPD+ subjects sponsored by the US CDC; a variety of phase II trials of various immunoadjuvants for TB sponsored by NIH/NIAID; a phase I/II trial of a NNRTI (nevirapine) for preventing mother-to-child HIV transmission sponsored by Boehringer Ingelheim Pharmaceuticals, Inc  and Africa’s first HIV preventative trial (AlVAC-vCP250) sponsored by Pasteur-Merieux Connaught and NIH-NIAID. He also directed the Clinical and Data Coordinating Center for the NIH’s Tuberculosis Research and Prevention Unit (TBRU) based at CWRU. He has over 50 peer-reviewed publications and 100 peer-reviewed abstracts presented at national and international conferences.

Earl W. Hulihan, MS

Mr. Hulihan has functioned in the Global GXP Regulatory Environment for over 30 years, primarily in the areas of Quality Assurance, Regulatory Affairs, Clinical Research, Drug Development, Drug Safety and Quality Systems.  He is currently the Corporate Compliance Officer and Senior Vice President of Regulatory Compliance at Medidata Solutions Worldwide, a leading global provider of clinical development solutions.  In addition he has held several senior management positions in the pharmaceutical industry including CROs.  Mr. Hulihan is a consultant to the FDA as well as to its European and Asian counterparts.  He is a contributing author to several textbooks on Quality Assurance, HIPAA, GCPs and computerized systems for clinical research.  He has received top honors from several organizations including the Drug Information Association and has been appointed as a visiting professor to Shanghai University of Traditional Chinese Medicine.

Elizabeth G. Marshall, PhD

Associate Professor
Division of Epidemiology, UMDNJ School of Public Health

Dr. Marshall teaches introductory epidemiology and conducts epidemiologic research, primarily in the areas of environmental and occupational health.  She has published extensively on environmental exposures, birth outcomes, and prevention of occupational disease and injury.  Prior to academic work at UMDNJ, Dr. Marshall was a researcher and manager with the New York State Department of Health, directing research, surveillance, and public response efforts in environmental and occupational health.  She holds a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill.

Brendan O'Neill

Brendan O'Neill is an associate director for the Patient Recruitment Specialist group at Merck Research Labs. He has been at Merck since 2000 and has held various positions in the Clinical Research Operations group. Currently, Brendan is supporting 30 recruitment specialists developing strategic and tactical recruitment plans for Merck's global clinical development programs. Brendan holds a BS in Pharmaceutical Marketing from St. Joseph's University and he is one of the first students to complete the Patient Recruitment Certificate Program at UMDNJ.

James L. Parmentier, PhD

Dr. Parmentier is currently Associate Director of the Clinical Investigation Program at the MGH Institute of Health Professions.  He has a wide variety of basic science and clinical trial experiences including identifying the mechanisms of action of venoms and insecticides as well as in developing medical devices for transdermal delivery of anesthetic agents.  In addition Dr. Parmentier has worked as a Project Manager responsible for clinical trial design and the management of drug and medical devices for several pharmaceutical companies and contract research organizations including Cato Research and Astra, US.  He also is an HIV/AIDS Advisor to the International Health Organization.

Robin Ratkowski, MSJ

Robin is a recent graduate from Seton Hall University School of Law, Master of Science in Jurisprudence (M.S.J.) program, majoring in Health Law. Robin has over eleven years experience in the health care industry. She was previously a Research Scientist at Cordis a Johnson & Johnson company in Warren, NJ, where she worked primarily in Advanced R&D supporting the development of medical devices and combination drug medical devices. Her experience includes materials research for cardiovascular, endovascular and neurovascular medical devices. She has extensive experience in FDA, GxP ISO, and ICH, and 21 CFR Part 11 compliance and regulations, including regulatory submission support, first in human clinical trial support and laboratory quality systems and compliance. Robin provided significant support to the research, development, FDA submission and post-market approval for Cypher, the first drug-eluting stent on the market in the US, for which she received a J&J VP of R&D award for technical excellence in materials research. Robin holds a BS in Environmental Science with a concentration in biology and chemistry.

Masayuki Shibata, Ph.D.

Masayuki Shibata, Ph.D. is an Associate Professor of Biomedical Informatics, in the Department of Health Informatics. He is an experienced computational biology - bioinformatics scientist with special interests in drug discovery and development. His general research interest lies in the development of computational tools and their applications to drug design. Specifically, he is interested in the use of bioinformatics and computational biology algorithms towards the elucidation of structure/function relationships of biological and pharmaceutical molecules through an integration of all available biological, biochemical, pharmacological, chemical and physical data.

Dr. Shibata has authored and co-authored more than 60 articles in various areas of molecular modeling and computational chemistry/biology - bioinformatics. His current research projects include: 1) Use of Bioinformatics and Chemoinformatics databases/tools for Design of Cancer Therapeutic Agents; 2) Structure-Function Relationship of Transforming Growth Factor-Beta (TGF-ß) and Its Role in Cell Growth; 3) Integration of Clinical and Biomedical Data in Drug Discovery and Development.

Shankar Srinivasan, MSc, PhD

Dr. Srinivasan is currently an Associate Professor in the Department of Health Informatics at the UMDNJ School of Health Related Professions. Prior to joining UMDN, Dr. Srinivasan taught in universities in Singapore and Australia. His research interests are mainly in the areas of health care data management, neuro-fuzzy systems and enterprise wide health care web services. He has published and/or presented over 60 research papers in various refereed international conference proceedings and journals.